Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medical therapy for acromegaly.

C B Newman1

  • 1Department of Clinical Medicine, New York University School of Medicine, New York, USA.

Endocrinology and Metabolism Clinics of North America
|April 20, 1999
PubMed
Summary

Somatostatin analogues and dopamine agonists treat acromegaly, with analogues being more effective. Surgery is preferred for microadenomas, while medical therapy is an option for macroadenomas or non-surgical candidates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimally invasive thoracic corpectomy and anterior fusion in a patient with metastatic disease: case report and review of the literature.

Minimally invasive neurosurgery : MIN·2009
Same author

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).

Diabetologia·2008
Same author

Percutaneous axial lumbar interbody fusion (AxiaLIF) of the L5-S1 segment: initial clinical and radiographic experience.

Minimally invasive neurosurgery : MIN·2008
Same author

Octreotide as primary therapy for acromegaly.

The Journal of clinical endocrinology and metabolism·1998
Same author

Acromegaly.

Current therapy in endocrinology and metabolism·1997
Same author

Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.

The Journal of clinical endocrinology and metabolism·1995

Area of Science:

  • Endocrinology
  • Oncology

Background:

  • Acromegaly is a disorder caused by excess growth hormone (GH).
  • Somatostatin analogues and dopamine agonists are primary medical treatments.
  • Treatment decisions involve drug efficacy, side effect profiles, and patient factors.

Purpose of the Study:

  • To review the current evidence for medical therapy in acromegaly.
  • To compare the efficacy of somatostatin analogues and dopamine agonists.
  • To discuss the role of medical therapy as primary versus secondary treatment.

Main Methods:

  • Literature review of studies on somatostatin analogues and dopamine agonists for acromegaly.
  • Analysis of data on treatment efficacy, tumor shrinkage, and biochemical cure.
  • Comparison of medical therapy with surgical outcomes.

Main Results:

  • Somatostatin analogues normalize IGF-1 in 60-65% of patients and reduce GH levels, but tumor shrinkage is limited to 40%.
  • Surgery offers a higher chance of cure for microadenomas (>=70%).
  • For macroadenomas with low surgical resection probability, somatostatin analogues are a viable primary option.

Conclusions:

  • Somatostatin analogues are generally more effective than dopamine agonists for acromegaly.
  • Surgery remains the preferred primary treatment for GH-secreting microadenomas.
  • Medical therapy is indicated for patients refusing surgery, poor surgical candidates, or those with macroadenomas where complete resection is unlikely.

Related Experiment Videos